相关实验视频
Updated: Jun 10, 2025

13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
17.5K
开启治疗前沿:利用人工智能在神经退行性疾病的药物发现中发挥作用
Bilal Nehmeh1, Joseph Rebehmed2, Riham Nehmeh3
1Department of Physical Sciences, Lebanese American University, Beirut 1102-2801, Lebanon.
Drug discovery today
|October 20, 2024
概括
人工智能 (AI) 加快了对神经退行性疾病 (NDs) 的药物发现. 人工智能有助于识别新目标,优化候选药物,并为这些具有挑战性的疾病推进个性化医疗.
科学领域:
- * 神经科学和药理学
- * 计算生物学和生物信息学
- * 医学中的人工智能
背景情况:
- *神经退行性疾病 (NDs) 由于有效治疗方法有限和社会成本较高,造成了重大的全球健康挑战.
- *传统的药物发现管道是漫长的,昂贵的,并且往往产生有限的成功,特别是在复杂的NDs.
- *人工智能 (AI) 的整合提供了一种转变性的方法来克服这些局限性.
研究的目的:
- * 审查人工智能的当前应用,以加速神经退行性疾病的药物发现.
- * 探索AI在识别新型治疗点和优化候选药物的潜力.
- *讨论人工智能在推进个人化医学策略中的作用.
主要方法:
- * 对用于神经退行性疾病研究和药物开发的AI技术进行全面的文献综述.
- *分析人工智能对目标识别,领先优化和临床试验加速的影响.
- * 检查了在临床前和临床环境中展示AI驱动成功的案例研究.
主要成果:
- *人工智能显著提高了对NDs潜在治疗点的识别速度和效率.
- *机器学习模型在预测候选药物的疗效和毒性方面表现出有效性,降低了失败率.
- *人工智能通过分析复杂的患者数据,促进了个性化治疗方法的开发.
结论:
- *人工智能是彻底改变神经退行性疾病疗法发现和开发的关键技术.
- *持续的跨学科合作和道德考虑对于最大限度地发挥人工智能的潜力至关重要.
- *人工智能驱动的方法有望加速为ND患者提供新和个性化的治疗方法.
相关概念视频
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
101
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
101
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Structure-Activity Relationships and Drug Design
622
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
622

